Health-Related Quality of Life of Patients With Multiple Myeloma Treated in Routine Clinical Practice in France

Abstract

Health-related quality of life (HRQoL) is an important consideration in the management of multiple myeloma (MM); however, real-world data are lacking. This observational study assessed the associations between treatment factors and HRQoL. Higher HRQoL scores were associated with good treatment response, few adverse events, and longer treatment duration. Effective MM treatments can therefore help improve and sustain HRQoL. Introduction: New therapies for multiple myeloma (MM) have improved life expectancy, but health-related quality of life (HRQoL) data from patients with MM in the real-world setting are lacking. This study, conducted in France, explored the associations between treatment outcomes and HRQoL in patients with MM. Patients and Methods: This observational, cross-sectional, multicenter study enrolled patients (! 18 years old) with symptomatic MM who had consulted a physician at least once between February and March 2016. HRQoL was assessed using the European Organization for Research and Treatment of Cancer (EORTC) Core Quality of Life questionnaire (QLQ-C30) and the Quality of Life Multiple Myeloma module (QLQ-MY20). Results: In total, 445 patients were included in the study; 402 (90%) completed the EORTC QLQ-C30 and QLQ-MY20 questionnaires. HRQoL decreased significantly with treatment line. Patients in the first treatment-free interval had relatively high scores. At later lines, patients receiving active treatment had better scores than those whose treatment had ended. High EORTC QLQ-C30 global health status scores were associated with good treatment response, few adverse events, and long duration of treatment, and were strongly influenced by the Eastern Cooperative Oncology Group performance status. Global health status scores correlated well with the 4 items of the QLQ-MY20 (future perspective, 0.46; body image, 0.41; disease symptoms, À0.57; side effects of treatment, À0.53). Conclusion: Effective treatment options in MM can help maintain HRQoL by influencing treatment response levels and delaying disease progression.

Health- Related Quality of Life for Multiple Myeloma Patients with Bone Metastases in Indonesia: A Cross-Sectional Study

“…Furthermore, health economics increasingly focus on this aspect, in addition to the clinical outcomes of patients (Fitzpatrick and Davies, 1998). However, the existence of this related information is highly limited, and the benefits in real-time clinical practice are unclear (Despiégel et al, 2019).…”

“…These findings were also similar to what was found by the previous study in France. Despiégel et al, (2019) stated that symptom score for fatigue and pain were particularly high in MM patients with supportive care as measured using EORTC QLQ-C30 (Despiégel et al, 2019). EORTC QLQ-C30.…”

Towards the integration of patient-reported outcomes into the global clinical management of multiple myeloma

“…Given that MM typically affects elderly patients with approximately one-third of patients being older than 75 years at the time of diagnosis, the incidence is rising due to population aging [3]. Therefore, their frailty, which may include the decline in functional capacities due to diseaserelated symptoms as well as to medical comorbidities, cognitive impairment, and polypharmacy, should be carefully considered to best evaluate potential implications for treatment discontinuation, therapeutic efficacy, and health-related quality of life (HRQOL) impact [3][4][5][6]. During their disease history, many MM patients may receive multiple lines of therapies and live with their illness for many years experiencing disease complications as well as treatment-related symptoms [1,2,5].…”

“…During their disease history, many MM patients may receive multiple lines of therapies and live with their illness for many years experiencing disease complications as well as treatment-related symptoms [1,2,5]. Briefly, patients with newly diagnosed MM (NDMM), according to their fitness, should receive a frailty-oriented treatment [3], which often consist of a combination of drugs with specific toxicity profiles [1][2][3][4][5][6]. Therefore, effective treatment options in MM can help maintain HRQOL by influencing treatment response levels and delaying disease progression [1,3].…”

“…Unfortunately, the use of PRO assessment in reallife studies has been less common but still informative. For example, a recent study in RRMM patients showed that HRQOL decreased significantly with treatment lines [4]. This evidence is particularly relevant as there is paucity of evidence-based information on PROs in RRMM patients [15].…”